Aducanumab in Alzheimer's disease: A critical update.

Ashique, S; Sirohi, E; Kumar, S; Rihan, M; Mishra, N; Bhatt, S; Gautam, RK; Singh, SK; Gupta, G; Chellappan, DK; Dua, K

Aducanumab in Alzheimer's disease: A critical update.

Ashique, S Sirohi, E Kumar, S Rihan, M Mishra, N Bhatt, S Gautam, RK Singh, SK Gupta, G Chellappan, DK Dua, K

Permalink

Publisher:: Bentham Science Publishers
Publication Type:: Journal Article
Citation:: Current Medicinal Chemistry, 2024, 31, (31), pp. 5004-5026
Issue Date:: 2024-07-27

Closed Access

	Filename	Description	Size
	23250951_15283557950005671.pdf	Published version	2.86 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Ashique, S
dc.contributor.author	Sirohi, E
dc.contributor.author	Kumar, S
dc.contributor.author	Rihan, M
dc.contributor.author	Mishra, N
dc.contributor.author	Bhatt, S
dc.contributor.author	Gautam, RK
dc.contributor.author	Singh, SK
dc.contributor.author	Gupta, G
dc.contributor.author	Chellappan, DK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2024-10-08T01:23:47Z
dc.date.available	2023-05-19
dc.date.available	2024-10-08T01:23:47Z
dc.date.issued	2024-07-27
dc.identifier.citation	Current Medicinal Chemistry, 2024, 31, (31), pp. 5004-5026
dc.identifier.issn	0929-8673
dc.identifier.issn	1875-533X
dc.identifier.uri	http://hdl.handle.net/10453/181226
dc.description.abstract	Alzheimer's disease (AD) is a complex neurological disorder that results in cognitive decline. The incidence rates of AD have been increasing, particularly among individuals 60 years of age or older. In June 2021, the US FDA approved aducanumab, the first humanized monoclonal antibody, as a potential therapeutic option for AD. Clinical trials have shown this drug to effectively target the accumulation of Aβ (beta-amyloid) plaques in the brain, and its effectiveness is dependent on the dosage and duration of treatment. Additionally, aducanumab has been associated with improvements in cognitive function. Biogen, the pharmaceutical company responsible for developing and marketing aducanumab, has positioned it as a potential breakthrough for treating cerebral damage in AD. However, the drug has raised concerns due to its high cost, limitations, and potential side effects. AD is a progressive neurological condition that affects memory, cognitive function, and behaviour. It significantly impacts the quality of life of patients and caregivers and strains healthcare systems. Ongoing research focuses on developing disease-modifying therapies that can halt or slow down AD progression. The pathogenesis of AD involves various molecular cascades and signaling pathways. However, the formation of extracellular amyloid plaques is considered a critical mechanism driving the development and progression of the disease. Aducanumab, as a monoclonal antibody, has shown promising results in inhibiting amyloid plaque formation, which is the primary pathological feature of AD. This review explores the signaling pathways and molecular mechanisms through which aducanumab effectively prevents disease pathogenesis in AD.
dc.format	Print
dc.language	eng
dc.publisher	Bentham Science Publishers
dc.relation.ispartof	Current Medicinal Chemistry
dc.relation.isbasedon	10.2174/0929867331666230727103553
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0304 Medicinal and Biomolecular Chemistry, 0601 Biochemistry and Cell Biology, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.subject.classification	3404 Medicinal and biomolecular chemistry
dc.subject.mesh	Alzheimer Disease
dc.subject.mesh	Humans
dc.subject.mesh	Antibodies, Monoclonal, Humanized
dc.subject.mesh	Amyloid beta-Peptides
dc.subject.mesh	Animals
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Alzheimer Disease
dc.subject.mesh	Amyloid beta-Peptides
dc.subject.mesh	Antibodies, Monoclonal, Humanized
dc.title	Aducanumab in Alzheimer's disease: A critical update.
dc.type	Journal Article
utslib.citation.volume	31
utslib.location.activity	United Arab Emirates
utslib.for	0304 Medicinal and Biomolecular Chemistry
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/Faculty of Health/School of Public Health
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)/Associate Member
pubs.organisational-group	University of Technology Sydney/UTS Groups/Australian Research Consortium in Complementary and Integrative Medicine (ARCCIM)
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2024-10-08T01:23:46Z
pubs.issue	31
pubs.publication-status	Published online
pubs.volume	31
utslib.citation.issue	31

Abstract:

Alzheimer's disease (AD) is a complex neurological disorder that results in cognitive decline. The incidence rates of AD have been increasing, particularly among individuals 60 years of age or older. In June 2021, the US FDA approved aducanumab, the first humanized monoclonal antibody, as a potential therapeutic option for AD. Clinical trials have shown this drug to effectively target the accumulation of Aβ (beta-amyloid) plaques in the brain, and its effectiveness is dependent on the dosage and duration of treatment. Additionally, aducanumab has been associated with improvements in cognitive function. Biogen, the pharmaceutical company responsible for developing and marketing aducanumab, has positioned it as a potential breakthrough for treating cerebral damage in AD. However, the drug has raised concerns due to its high cost, limitations, and potential side effects. AD is a progressive neurological condition that affects memory, cognitive function, and behaviour. It significantly impacts the quality of life of patients and caregivers and strains healthcare systems. Ongoing research focuses on developing disease-modifying therapies that can halt or slow down AD progression. The pathogenesis of AD involves various molecular cascades and signaling pathways. However, the formation of extracellular amyloid plaques is considered a critical mechanism driving the development and progression of the disease. Aducanumab, as a monoclonal antibody, has shown promising results in inhibiting amyloid plaque formation, which is the primary pathological feature of AD. This review explores the signaling pathways and molecular mechanisms through which aducanumab effectively prevents disease pathogenesis in AD.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/181226